Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 174-180

  Tobinai, Kensei ^a   Watanabe, Takashi ^b   Ogura, Michinori ^b   Morishima, Yasuo ^b   Ogawa, Yoshiaki ^b   Ishizawa, Ken Ichi ^b   Minami, Hironobu ^b   Utsunomiya, Atae ^b   Taniwaki, Masafumi ^b   Terauchi, Takashi ^b   Nawano, Shigeru ^b   Matsusako, Masaki ^b   Matsuno, Yoshihiro ^b   Nakamura, Shigeo ^b   Mori, Shigeo ^b   Ohashi, Yasuo ^b   Hayashi, Masaki ^b   Seriu, Taku ^b   Hotta, Tomomitsu ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; VIDARABINE PHOSPHATE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BRONCHITIS; CANCER FATIGUE; CANCER REGISTRY; CANCER RELAPSE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HEADACHE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATURIA; HERPES ZOSTER; HUMAN; INSOMNIA; INTERSTITIAL PNEUMONIA; LARYNX CANCER; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RASH; SIDE EFFECT; SINUS TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECURRENCE; VIDARABINE PHOSPHATE;

EID: 33644845422     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.9313     Document Type: Article

References (30)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
2. Dana BW, Dahlberg S, Nathwani B, et al: Long term follow-up of patients with low grade lymphomas treated with doxorubicin based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
4. Igarashi T, Kobayashi Y, Ogura M, et al: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 13:928-943, 2002
5. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
6. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711-4716, 2004
7. Zhu Q, Tan DC, Samuel M, et al: Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: A systematic review and meta-analysis. Leuk Lymphoma 45:2239-2245, 2004
8. Hochster HS, Kim KM, Green MD, et al: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
9. Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992
10. Whelan JS, Davis CL, Rule S, et al: Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120-123, 1991
11. Zinzani PL, Lauria F, Rondelli D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993
12. Klasa RJ, Meyer RM, Shustik C, et al: Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 20:4649-4654, 2002
13. Foran JM, Oscier D, Orchard J, et al: Pharmacokinetic study of single dose of oral fludarabine phosphate in patients with low-grade non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 17:1574-1579, 1999
14. Boogaerts MA, Hoof AV, Catovsky D, et al: Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 19:4252-4258, 2001
15. Tobinai K, Watanabe T, Hotta T, et al: Phase I study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma (B-NHL). Proc Am Soc Clin Oncol 22:599, 2003 (abstr 2411)
16. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
17. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
18. Mason DY, Comans-Bitter WM, Cordell JL, et al: Antibody L26 recognizes an intracellular episode on the B-cell-associated CD20 antigen. Am J Pathol 136:1215-1222, 1990
19. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999
20. Solal-Celigny P, Roy P, Colombai P, et al: Follicular Lymphoma International Prognostic Index. Blood 104:1258-1265, 2004
21. Lymphoma Study Group of Japanese Pathologists: The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
22. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
23. Lenz G, Hiddemann W, Dreyling M: The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 101:883-893, 2004
24. Falkson C: Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma. Am J Clin Oncol 19:268-270, 1996
25. Decaudin D, Bosq J, Tertian G, et al: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16:579-583, 1998
26. Foran JM, Rohatiner AZ, Coiffier B, et al: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999
27. Zinzani PL, Magagnoli M, Moretti L, et al: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 18: 773-779, 2000
28. Cheson BD, Vena DA, Barrett J, et al: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454-2460, 1999
29. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996
30. Czuczman MS, Koryzna A, Mohr A, et al: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694-704, 2005